Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

831 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin-based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials.
Maeda H, Hazama S, Iwamoto S, Oba K, Tsunedomi R, Okayama N, Suehiro Y, Yamasaki T, Nakagami Y, Suzuki N, Nagano H, Sakamoto J, Mishima H, Nagata N. Maeda H, et al. Among authors: iwamoto s. Oncol Lett. 2019 Nov;18(5):4555-4562. doi: 10.3892/ol.2019.10787. Epub 2019 Aug 29. Oncol Lett. 2019. PMID: 31611963 Free PMC article.
The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues.
Okayama N, Nishioka M, Hazama S, Sakai K, Suehiro Y, Maekawa M, Sakamoto J, Iwamoto S, Kato T, Mishima H, Oka M, Hinoda Y. Okayama N, et al. Among authors: iwamoto s. Jpn J Clin Oncol. 2011 Feb;41(2):165-71. doi: 10.1093/jjco/hyq173. Epub 2010 Oct 5. Jpn J Clin Oncol. 2011. PMID: 20926413
A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial.
Iwamoto S, Ooki A, Morita S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Sudo T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K. Iwamoto S, et al. Cancer Med. 2018 Sep;7(9):4217-4227. doi: 10.1002/cam4.1623. Epub 2018 Jul 26. Cancer Med. 2018. PMID: 30051609 Free PMC article. Clinical Trial.
Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study).
Nagata N, Maeda H, Ishibashi K, Hirata K, Makiyama A, Iwamoto S, Takemoto H, Imasato M, Yoshida Y, Munemoto Y, Tanaka C, Morita Y, Hotta Y, Toyofuku A, Nagasaka T, Morita S, Sakamoto J, Mishima H. Nagata N, et al. Among authors: iwamoto s. Med Oncol. 2019 Apr 24;36(6):46. doi: 10.1007/s12032-019-1254-4. Med Oncol. 2019. PMID: 31020480 Clinical Trial.
Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
Ooki A, Morita S, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Suto T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K. Ooki A, et al. Among authors: iwamoto s. Cancer Med. 2020 Mar;9(5):1779-1789. doi: 10.1002/cam4.2826. Epub 2020 Jan 21. Cancer Med. 2020. PMID: 31962002 Free PMC article. Clinical Trial.
Phase II study of 5-fluorouracil-leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802).
Ohta T, Kato T, Kawakami H, Miyake Y, Goto M, Iwamoto S, Otsuji T, Nakamura M, Sugimoto N, Okamura S, Kotaka M, Tsujie M, Tokunaga Y, Mishima H, Hata T, Shimokawa T, Kurokawa Y, Satoh T. Ohta T, et al. Among authors: iwamoto s. Int J Clin Oncol. 2020 Jul;25(7):1291-1298. doi: 10.1007/s10147-020-01656-3. Epub 2020 Mar 26. Int J Clin Oncol. 2020. PMID: 32219630 Clinical Trial.
831 results